Stay updated on Empagliflozin US Comparative Effectiveness Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin US Comparative Effectiveness Clinical Trial page.

Latest updates to the Empagliflozin US Comparative Effectiveness Clinical Trial page
- ChecktodayChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.8.0 to v3.8.1, while the study information remains unchanged.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe ClinicalTrials.gov record for the EMPRISE study is available again, describing its real-world comparison of empagliflozin and other diabetes treatments, study measures, and completed status.SummaryDifference47%

- Check21 days agoChange DetectedThe footer now identifies the site revision as v3.8.0 instead of v3.7.2. The page continues to show a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH notice about the terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error response; the study record remains inaccessible.SummaryDifference1%

- Check35 days agoChange DetectedThe revision label in the footer changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check42 days agoChange DetectedThe study page continues to show a 403 Forbidden error instead of a study record, with the footer showing revision v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Empagliflozin US Comparative Effectiveness Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin US Comparative Effectiveness Clinical Trial page.